Flyer

Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 14
  • Journal CiteScore: 3.77
  • Journal Impact Factor: 4.09
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • International Committee of Medical Journal Editors (ICMJE)
  • Zenodo
Share This Page

Cold isostatic pressing of hydrating calcium sulfate to produce parenteral slow-release drug formulations

Joint Event on 36th World Cancer Conference & 3rd Edition of International Conference on Colorectal Cancer
October 11-13, 2018 Zurich, Switzerland

S. Gruden, N Axen and M Hassan

LIDDS AB, Sweden Karolinska Institutet, Sweden

Posters & Accepted Abstracts: Arch Cancer Res

Abstract:

This lecture will address a novel principle to produce slow-release depots containing a water-solvable calcium sulfate formulation encapsulating the anti-androgen substance 2-hydroxyflutamide in a microstructurally designed calcium sulfate matrix. The microstructure of the solidified depot consists of a composite of porous and dense material providing a combination of faster and slower release features. By mixing the drug loaded powder, consisting of densified and non-densified granular components, with an aqueous sodium carboxymethyl cellulose solution, an injectable suspension is formulated, which is injectable and which solidifies in vivo as a result of the ability of calcium sulfate to solidify by hydration. This technology has been tested in four clinical trials with injection into the prostate gland in order to decrease the prostate volume and to delay the prostate cancer progression. In addition to these subjects, attendees of this lecture will be familiarized with the future promising potential therapy areas for intra-tumoral injection which are close to enter clinical trial evaluation in cancer patients.

Biography :

E-mail:

stefan.gruden@liddspharma.com stefan.gruden@ki.se